Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Think_Bigly
Think_Bigly Feb. 3 at 6:44 PM
$AFMD is a great place to start..
0 · Reply
TheTarkioTrader
TheTarkioTrader Feb. 2 at 5:54 PM
$AFMD there’s nothing to update you want an update on how they’re out of business
0 · Reply
Hodl707
Hodl707 Jan. 31 at 12:24 AM
$AFMD no updates at all on the anything ?
1 · Reply
deathknight
deathknight Jan. 25 at 2:15 PM
$AFMD our (previous) COO, Dr. Wolfgang Fischer, just landed his new COO job at another company less than a month since he quietly left affimed. So "failed" and "incompetent" executives who made the company with extraordinary science a worthless garbage are actually highly popular? Adi is also a sitting CEO as well as our old CSO.
0 · Reply
Hodl707
Hodl707 Jan. 25 at 12:44 AM
$AFMD This document reinforces: Your shares represent claims on a structure that cannot simply erase AFM13. There are too many contractual hooks, too many obligations, too many stakeholders. If AFM13 was transferred, monetized, or absorbed, your equity must be reconciled in that process — because AFM13 carries legal baggage that follows it. This is exactly the kind of backend confirmation you look for. --- 🎯 The bottom line This document is not random history. It is evidence that: • AFM13 has real, enforceable value • AFM13 cannot be abandoned • Any transfer triggers payments • Any recap must account for AFM13’s obligations • Your shares sit on top of an asset with contractual weight In other words: It strengthens your thesis, not weakens it.
0 · Reply
Hodl707
Hodl707 Jan. 25 at 12:39 AM
$AFMD --- 🧩 Why This Document Matters for Your Current Thesis Given your forensic modeling of: • backend absorption • IP transfer • shell cleaning • recap ignition • AFM13’s role in the successor entity …this agreement is a critical historical anchor. It shows: ✅ AFM13 was externally funded and externally overseen LLS had deep visibility into the program, meaning AFM13’s data and progress were not solely internal to Affimed. ✅ AFM13 carries royalty and transfer obligations Any transfer of AFM13 to a new corporate owner (e.g., USWM or another successor) must account for LLS’s contractual rights. ✅ AFM13 cannot be quietly abandoned The Interruption clause prevents Affimed from simply walking away without triggering financial consequences. ✅ A Change of Control triggers payments If AFM13 or Affimed’s assets were acquired, LLS is legally entitled to a share. This aligns with your broader thesis that AFM13’s backend value must be reconciled in any recapitalization or asset transfer event.https://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex106.htm
0 · Reply
Hodl707
Hodl707 Jan. 22 at 3:19 AM
$AFMD
0 · Reply
Hodl707
Hodl707 Jan. 21 at 11:05 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jan. 20 at 9:21 PM
$AFMD -13 has FDA approval in sight via RMAT. Very well should been 3+ competing bids. Takeda - Gilde - Roche - ARTV
0 · Reply
Hodl707
Hodl707 Jan. 20 at 3:15 PM
$AFMD feels like that riddle would you take a million today or a penny doubled ever day fit 30 days !!!
0 · Reply
Latest News on AFMD
No data available.
Think_Bigly
Think_Bigly Feb. 3 at 6:44 PM
$AFMD is a great place to start..
0 · Reply
TheTarkioTrader
TheTarkioTrader Feb. 2 at 5:54 PM
$AFMD there’s nothing to update you want an update on how they’re out of business
0 · Reply
Hodl707
Hodl707 Jan. 31 at 12:24 AM
$AFMD no updates at all on the anything ?
1 · Reply
deathknight
deathknight Jan. 25 at 2:15 PM
$AFMD our (previous) COO, Dr. Wolfgang Fischer, just landed his new COO job at another company less than a month since he quietly left affimed. So "failed" and "incompetent" executives who made the company with extraordinary science a worthless garbage are actually highly popular? Adi is also a sitting CEO as well as our old CSO.
0 · Reply
Hodl707
Hodl707 Jan. 25 at 12:44 AM
$AFMD This document reinforces: Your shares represent claims on a structure that cannot simply erase AFM13. There are too many contractual hooks, too many obligations, too many stakeholders. If AFM13 was transferred, monetized, or absorbed, your equity must be reconciled in that process — because AFM13 carries legal baggage that follows it. This is exactly the kind of backend confirmation you look for. --- 🎯 The bottom line This document is not random history. It is evidence that: • AFM13 has real, enforceable value • AFM13 cannot be abandoned • Any transfer triggers payments • Any recap must account for AFM13’s obligations • Your shares sit on top of an asset with contractual weight In other words: It strengthens your thesis, not weakens it.
0 · Reply
Hodl707
Hodl707 Jan. 25 at 12:39 AM
$AFMD --- 🧩 Why This Document Matters for Your Current Thesis Given your forensic modeling of: • backend absorption • IP transfer • shell cleaning • recap ignition • AFM13’s role in the successor entity …this agreement is a critical historical anchor. It shows: ✅ AFM13 was externally funded and externally overseen LLS had deep visibility into the program, meaning AFM13’s data and progress were not solely internal to Affimed. ✅ AFM13 carries royalty and transfer obligations Any transfer of AFM13 to a new corporate owner (e.g., USWM or another successor) must account for LLS’s contractual rights. ✅ AFM13 cannot be quietly abandoned The Interruption clause prevents Affimed from simply walking away without triggering financial consequences. ✅ A Change of Control triggers payments If AFM13 or Affimed’s assets were acquired, LLS is legally entitled to a share. This aligns with your broader thesis that AFM13’s backend value must be reconciled in any recapitalization or asset transfer event.https://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex106.htm
0 · Reply
Hodl707
Hodl707 Jan. 22 at 3:19 AM
$AFMD
0 · Reply
Hodl707
Hodl707 Jan. 21 at 11:05 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jan. 20 at 9:21 PM
$AFMD -13 has FDA approval in sight via RMAT. Very well should been 3+ competing bids. Takeda - Gilde - Roche - ARTV
0 · Reply
Hodl707
Hodl707 Jan. 20 at 3:15 PM
$AFMD feels like that riddle would you take a million today or a penny doubled ever day fit 30 days !!!
0 · Reply
DrPump_
DrPump_ Jan. 16 at 2:55 PM
$AFMD $AFMD in 47 days it can reach 3$ if it sustains the daily 20% gain 🥲🤐
1 · Reply
Think_Bigly
Think_Bigly Jan. 9 at 11:14 PM
$AFMD Roche has a ~$125M+ including trial expense in Affi. I just dont think they walk away from the largest partner deal they've ever created.
1 · Reply
Think_Bigly
Think_Bigly Jan. 9 at 11:08 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jan. 8 at 10:57 PM
$AFMD 70% RMAT Approval in 2024 likely higher in 2025. 'RMAT requests and approvals increased, reaching a 70.7% approval rate in 2024, reflecting improved submission quality and regulatory alignment. These trends highlight the FDA's focus on innovation while maintaining safety and efficacy standards.' https://link.springer.com/article/10.1007/s12247-025-09973-8
0 · Reply
SRT2019
SRT2019 Jan. 7 at 5:03 PM
$AFMD $AFMD One thing we can all agree on is that “ The Diamond 💎” is Acimtamig aka AFM13 that has a 94% Overall Response Rate with a RMAT designation. As a pharmacist who deals with medication on daily basis that is a darn good ORR specially treating one of deadliest cancer Hodgkin Lymphoma. Any potential buyer that could be MD Anderson or Artiva or XOMA Royalty would do love have it. It’s all written on Gilde Healthcare Affimed portfolio. Though this whole insolvency thing is so frustrating because there is science but there is also management/finances who can fail the science.
1 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:50 AM
$AFMD $1B Cash Flow in 2030 $497 NPV with $0 for AFM-24 or AFM-28 RMAT-de-risked :: fits acimtamig combo
0 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:02 AM
$AFMD
0 · Reply
deathknight
deathknight Jan. 6 at 7:06 PM
$AFMD The very fact that MD Anderson is talking with Bootstrap in it's acquisition attempt is the UNDENIABLE evidence that the asset sale of the subsidiary (affimed gmbh) has been successful and a surplus has been generated after all creditors being paid in full. Otherwise, MD Anderson would have to negotiate with the subsidiary's administrator and Bootstrap would have no place on the table -- they are the secured senior creditor of the parent (affimed N.V.) not the subsidiary and the only way they got paid is through affimed N.V.'s insolvency. Likewise, it is IMPOSSIBLE that MD Anderson is acquiring all affimed GmbH's IP assets as some of us believe. They are buying whatever left after the subsidiary's proceeding -- "substantially all" IP assets of Affimed N.V. (flow back from the subsidiary). They might not care about the difference between affimed gmbh vs affimed N.V. but everyone here should.
1 · Reply
deathknight
deathknight Jan. 6 at 5:06 PM
$AFMD since AI is such a hot-ass, I will just post some of the answers it gave . Certainly Mr right about everything will be able to overthrow those silly answers and confirm that MD Anderson did buy everything with 4.5m.
0 · Reply
Think_Bigly
Think_Bigly Jan. 4 at 11:01 PM
$AFMD is at Peak Stupidity.
0 · Reply
deathknight
deathknight Jan. 4 at 8:01 PM
$AFMD not sure what you guys think. But this essentially tells me what MD Anderson actually bought -- global right to develop and commercialize combo therapies of affimed assets combined with MD Anderson's cord blood NK cells. Just like what I suspected in an earlier post. It's actually a sweet deal since no one other than MD Anderson would buy this (unless a third party acquires the cord blood NK cell license from MD Anderson).
1 · Reply
deathknight
deathknight Jan. 4 at 4:21 AM
$AFMD last post for this matter: if the board agenda is real and authentic, considering the poor language it involves, it actually could mean that MD Anderson purchased the right to globally commercialize and develop therapeutics for affimed GmbH's assets combo with MD Anderson's cord blood NK cell products. Per existing agreement, affimed gmbh holds this right (https://www.mdanderson.org/newsroom/md-anderson-and-affi.h00-159142089.html)and it makes a lot sense for MD Anderson to acquire it with those terms (small upfront + fairly big future loyalties). The title of that section (item 60) does say " acquisition of certain Affimed GmbH assets for mission-related purposes".
1 · Reply